556
Views
15
CrossRef citations to date
0
Altmetric
Articles

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report

, M.D., , M.D., Ph.D., A.B.I.M., F.R.C.P.C., , , M.D., C.C.F.P., F.C.F.P. & , M.D., M.Sc.
Pages 214-217 | Received 19 Jan 2016, Accepted 28 Mar 2016, Published online: 18 May 2016
 

ABSTRACT

Background: Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga plant, has shown potential to bring about transformative or spiritual experiences that have reportedly been associated with long-term abstinece. Although research on ibogaine is limited, an ibogaine subculture persists, offering unregulated ibogaine preparations for the treatment of addiction. Case presentation: We describe the case of a 37-year-old female with a 19-year history of severe OUD achieving an ongoing 18-month period of abstinence following a four-day ibogaine treatment. Her previous longest period of continuous abstinence from opioids was two months while on methadone. No safety issues associated with ibogaine were observed. Conclusions: A four-day treatment with ibogaine was succesful in achieving long-term remission of a previously treatment-refractory patient with severe OUD. While rigorous trials are required to establish safety and efficacy, future studies should seek to delineate the potential role of ibogaine or other molecules that may produce transformative experiences for individuals with substance use disorder.

Acknowledgments

We thank Carmen Rock for her administrative assistance.

Funding

The study was supported by the U.S. National Institutes of Health (R25DA037756). EW is partially supported by a Tier 1 Canada Research Chair in Inner City Medicine. MES is supported by a Michael Smith Foundation for Health Research Post-Doctoral fellowship award.

Additional information

Funding

The study was supported by the U.S. National Institutes of Health (R25DA037756). EW is partially supported by a Tier 1 Canada Research Chair in Inner City Medicine. MES is supported by a Michael Smith Foundation for Health Research Post-Doctoral fellowship award.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.